{
  "item1": "sold USSTC. addition, oral tobacco products segment includes oral nicotine pouches sold Helix. Substantially all oral tobacco products manufactured sold customers United States. Total oral tobacco products segment’s shipment volume 774.7 million units 2024, decrease 1.0% 2023.",
  "item7": "Non-GAAP Financial Measures report financial results accordance GAAP. However, management also reviews certain financial results, including OCI, OCI margins, net earnings diluted EPS, adjusted basis, which excludes certain income expense items management believes not part underlying operations. These items may include, example, loss early extinguishment debt, restructuring charges, asset impairment charges, acquisition, disposition integration-related items, equity investment-related special items, certain income tax items, charges associated tobacco health certain other litigation items, resolutions certain non-participating manufacturer (“NPM”) adjustment disputes under Master Settlement Agreement (“NPM Adjustment Items”). addition, management reviews ratio debt-to-Consolidated EBITDA, which use factor determine ability access capital markets make investments pursuit Vision.",
  "item2": "Prior period amounts been recast conform current period presentation amortization intangibles, which did not previously identify special item now exclude adjusted financial measures. See Non-GAAP Financial Measures discussion special items other business drivers affecting comparability statements earnings amounts reconciliations adjusted earnings adjusted diluted EPS, see Consolidated Operating Results Fewer Shares Outstanding: Fewer shares outstanding due shares repurchased under share repurchase programs. increase $35 million operations (which excludes impact special items shown table above) due primarily higher OCI. further details, see Consolidated Operating Results Operating Results Business Segment Non-GAAP Financial Measures report financial results accordance GAAP."
}